Revelation Financial Statements From 2010 to 2026

REVB Stock  USD 2.03  0.13  6.84%   
Revelation Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Revelation Biosciences' valuation are provided below:
Gross Profit
90.9 M
Market Capitalization
2.8 M
Earnings Share
325
We have found one hundred twenty available trending fundamental ratios for Revelation Biosciences, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Revelation Biosciences recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of January 31, 2026, Market Cap is expected to decline to about 4.1 M. The current year's Enterprise Value is expected to grow to about (3 M)

Revelation Biosciences Total Revenue

0.0

Check Revelation Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revelation Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 42.2 K, Total Revenue of 0.0 or Other Operating Expenses of 5.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.76. Revelation financial statements analysis is a perfect complement when working with Revelation Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Revelation Stock
Check out the analysis of Revelation Biosciences Correlation against competitors.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.

Revelation Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.7 MM1.1 B
Slightly volatile
Accounts Payable792.1 K705.3 K928.8 K
Pretty Stable
Cash5.6 M5.8 M69.3 M
Slightly volatile
Long Term Debt135.7 M200.3 M141.1 M
Slightly volatile
Net ReceivablesM8.8 M6.4 M
Slightly volatile
Good Will29.3 M30.8 M27 M
Slightly volatile
Short Term Investments7.8 B7.5 B2.5 B
Slightly volatile
Total Liabilities1.6 M1.7 M952.8 M
Slightly volatile
Long Term Investments192.4 M223.2 M173.8 M
Slightly volatile
Intangible Assets3.2 M2.6 M3.9 M
Slightly volatile
Total Current Liabilities1.6 M1.7 M971 M
Slightly volatile
Other Liabilities32.4 M58.3 M25.5 M
Slightly volatile
Other Current Assets57 K60 K3.7 M
Slightly volatile
Total Current Assets5.6 M5.9 M56.8 M
Slightly volatile
Common Stock44647030.2 M
Slightly volatile
Property Plant Equipment142.2 K149.7 K3.5 M
Slightly volatile
Short and Long Term Debt24.4 M27.4 M29.9 M
Slightly volatile
Short Term Debt2.5 M2.6 M17 M
Slightly volatile
Other Current LiabilitiesM1.3 M863.9 K
Slightly volatile
Non Current Assets Total48.2 K50.7 K4.4 M
Pretty Stable
Common Stock Shares Outstanding207.1 K197.2 K36.1 K
Slightly volatile
Liabilities And Stockholders Equity5.7 M7.6 M2.6 M
Slightly volatile
Cash And Short Term Investments6.5 M7.5 M5.2 M
Slightly volatile
Capital Stock446470703.1 K
Very volatile
Short and Long Term Debt Total13.4 K15.1 K16.5 K
Slightly volatile
Current Deferred Revenue2.3 M2.6 M2.9 M
Slightly volatile

Revelation Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses5.9 M7.2 M8.7 M
Slightly volatile
Total Operating Expenses12.9 M7.2 M14.8 M
Pretty Stable
Selling General Administrative3.8 MM17.3 M
Slightly volatile
Tax Provision11.2 M13.3 M9.4 M
Slightly volatile
Net Interest Income81.1 M106.8 M72.5 M
Slightly volatile
Interest Income105 M148.7 M95.6 M
Slightly volatile
Depreciation And Amortization36.1 K25.1 K110.5 K
Slightly volatile
Selling And Marketing Expenses21.4 K22.5 K101.8 K
Slightly volatile
Research Development4.4 M4.1 M1.7 M
Slightly volatile
Reconciled Depreciation26.1 K32.1 K19.9 K
Slightly volatile

Revelation Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation23.9 K25.1 K647.4 K
Slightly volatile
Total Cash From Financing Activities11 M11.6 M170 M
Slightly volatile
End Period Cash Flow5.6 M5.8 M45.8 M
Slightly volatile
Stock Based Compensation182.5 K152 K112.5 K
Slightly volatile
Begin Period Cash Flow15.6 M10.8 M50.9 M
Slightly volatile
Issuance Of Capital Stock7.8 M4.9 M8.2 M
Very volatile
Dividends Paid6.1 M6.9 M7.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables656.5 K964.6 K607.4 K
Slightly volatile
Capex To Depreciation0.750.795.7624
Slightly volatile
Payables Turnover0.06670.0410.0956
Slightly volatile
Cash Per Share41.443.5818.4 K
Slightly volatile
Days Payables Outstanding7.7 K9.2 K5.3 K
Slightly volatile
Income Quality1.041.13.9624
Slightly volatile
Net Debt To EBITDA0.560.740.3092
Slightly volatile
Current Ratio3.243.091.6973
Slightly volatile
Capex Per Share0.09560.113.2565
Pretty Stable
Interest Debt Per Share79.6689.6297.8218
Slightly volatile
Debt To Assets0.00660.00740.0081
Slightly volatile
Days Of Payables Outstanding7.7 K9.2 K5.3 K
Slightly volatile
Ebt Per Ebit1.781.71.0811
Slightly volatile
Quick Ratio3.243.091.6973
Slightly volatile
Net Income Per E B T0.340.390.422
Slightly volatile
Cash Ratio3.213.061.6464
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9832
Slightly volatile
Debt Ratio0.00660.00740.0081
Slightly volatile

Revelation Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.1 M4.4 M61.9 M
Slightly volatile

Revelation Fundamental Market Drivers

Forward Price Earnings0.8875
Cash And Short Term Investments6.5 M

Revelation Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Revelation Biosciences Financial Statements

Revelation Biosciences stakeholders use historical fundamental indicators, such as Revelation Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Revelation Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Revelation Biosciences' assets and liabilities are reflected in the revenues and expenses on Revelation Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Revelation Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.3 M
Cost Of Revenue32.1 K19.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:
Check out the analysis of Revelation Biosciences Correlation against competitors.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. Anticipated expansion of Revelation directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Revelation Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
325
Return On Assets
(0.53)
Return On Equity
(1.19)
Understanding Revelation Biosciences requires distinguishing between market price and book value, where the latter reflects Revelation's accounting equity. The concept of intrinsic value—what Revelation Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Revelation Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Revelation Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Revelation Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Revelation Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.